We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$169B
Turnover
4.85%
1-Year Est. Return
114.72%
This Fund
S&P 500
This Quarter
Est. Return
+4.87%
1 Year Est. Return
+114.72%
3 Year Est. Return
+234.44%
5 Year Est. Return
+291.25%
10 Year Est. Return
+1,263.36%
AUM
$102B
AUM Growth
+$1.43B
(+1.4%)
Cap. Flow
-$1.09B
Cap. Flow
% of AUM
-1.07%
Top 10 Holdings %
Top 10 Hldgs %
32.54%
Holding
287
New
14
Increased
80
Reduced
134
Closed
11
Avg Time Held
2.7
years
Top 10 Avg Time Held
3
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qiagen
QGEN
|
+$518M |
| 2 |
AstraZeneca
AZN
|
+$246M |
| 3 |
Alkermes
ALKS
|
+$172M |
| 4 |
Whirlpool
WHR
|
+$94.4M |
| 5 |
Eli Lilly
LLY
|
+$78.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
QGENF
QIAGEN NV
QGENF
|
+$534M |
| 2 |
Charles Schwab
SCHW
|
+$265M |
| 3 |
Amgen
AMGN
|
+$235M |
| 4 |
NVIDIA
NVDA
|
+$233M |
| 5 |
Microsoft
MSFT
|
+$177M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.82% |
| 2 | Healthcare | 22.95% |
| 3 | Industrials | 16.78% |
| 4 | Consumer Discretionary | 9.51% |
| 5 | Financials | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
DELISTED
Spirit Airlines, Inc.
SAVE
| $53M | 0.05% |
916,824
-16,800
| -2% | -$866K |
2013 Q2
14 quarters
|
|
152
Edwards Lifesciences
EW
$50.8B
| $52.5M | 0.05% |
1,680,000
| – | – |
2013 Q2
14 quarters
|
|
|
LGF.A
153
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
| $52.3M | 0.05% |
+1,942,500
| New | +$52.6M |
2016 Q4
0 quarters
|
|
154
Axcelis
ACLS
$3.55B
| $50.6M | 0.05% |
3,478,393
-6,907
| -0.2% | -$94K |
2014 Q1
11 quarters
|
|
155
Salesforce
CRM
$203B
| $50.3M | 0.05% |
734,110
+77,000
| +12% | +$5.59M |
2013 Q2
14 quarters
|
|
|
TPCO
156
DELISTED
Tribune Publishing Company Common Stock
TPCO
| $49.1M | 0.05% |
3,541,993
-8,875
| -0.2% | -$123K |
2014 Q3
9 quarters
|
|
157
Johnson Controls International
JCI
$89.4B
| $48.1M | 0.05% |
1,168,700
-60,500
| -5% | -$2.65M |
2016 Q3
1 quarter
|
|
|
LGF.B
158
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $47.7M | 0.05% |
+1,942,500
| New | +$49.6M |
2016 Q4
0 quarters
|
|
159
PepsiCo
PEP
$175B
| $47.1M | 0.05% |
450,000
| – | – |
2013 Q2
14 quarters
|
|
160
Charter Communications
CHTR
$12.6B
| $46.9M | 0.05% |
162,900
| – | – |
2016 Q2
2 quarters
|
|
161
Zimmer Biomet
ZBH
$18B
| $46.4M | 0.05% |
463,500
-2,369
| -0.5% | -$254K |
2013 Q2
14 quarters
|
|
162
DELISTED
Coterra Energy
CTRA
| $42.6M | 0.04% |
1,824,000
-876,900
| -32% | -$19.7M |
2013 Q2
14 quarters
|
|
163
American Express
AXP
$212B
| $42.6M | 0.04% |
574,600
-100
| -0% | -$6.92K |
2013 Q2
14 quarters
|
|
164
Travelers Companies
TRV
$80.1B
| $42.5M | 0.04% |
347,100
+15,700
| +5% | +$1.79M |
2016 Q2
2 quarters
|
|
165
GSK
GSK
$98.2B
| $42.1M | 0.04% |
875,188
-12,080
| -1% | -$597K |
2013 Q2
14 quarters
|
|
166
Newell Brands
NWL
$2.46B
| $42M | 0.04% |
941,760
+235,000
| +33% | +$11.4M |
2014 Q1
11 quarters
|
|
167
Hilton Worldwide
HLT
$77.2B
| $41.7M | 0.04% |
511,133
+164,366
| +47% | +$12.1M |
2015 Q2
6 quarters
|
|
|
MNTA
168
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $41.2M | 0.04% |
2,739,900
| – | – |
2013 Q2
14 quarters
|
|
169
General Dynamics
GD
$91.2B
| $41.1M | 0.04% |
+238,000
| New | +$38.9M |
2016 Q4
0 quarters
|
|
170
Kirby Corp
KEX
$7.24B
| $40.4M | 0.04% |
606,895
-16,950
| -3% | -$1.07M |
2013 Q2
14 quarters
|
|
171
DELISTED
Novadaq Technologies Inc.
NVDQ
| $40M | 0.04% |
5,643,449
-42,900
| -0.8% | -$389K |
2014 Q4
8 quarters
|
|
172
NOV
NOV
$6.64B
| $37.8M | 0.04% |
1,008,995
-206,800
| -17% | -$7.53M |
2013 Q2
14 quarters
|
|
173
DELISTED
Hawaiian Holdings, Inc.
HA
| $36.6M | 0.04% |
641,300
+18,800
| +3% | +$960K |
2014 Q2
10 quarters
|
|
174
DELISTED
Du Pont De Nemours E I
DD
| $35M | 0.03% |
476,500
| – | – |
2013 Q2
14 quarters
|
|
175
Cerus
CERS
$455M
| $33.9M | 0.03% |
7,800,000
| – | – |
2015 Q1
7 quarters
|
|
Similar funds
Primecap Management's Q4 2016 Portfolio in Review
As of Q4 2016, Primecap Management held 287 positions worth $102B, up 1.4% from $100B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Primecap Management's Q4 2016 filing shows 14 new, 80 increased, 134 reduced and 11 closed positions. Its largest new stake was Qiagen: 17,384,319 shares worth $536M. The largest sale was QIAGEN NV, an estimated $534M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 30% a quarter earlier, followed by Healthcare and Industrials.
- Primecap Management's largest Q4 2016 buy was Qiagen: 17,384,319 shares worth $536M.
- Primecap Management added most to AstraZeneca in Q4 2016, an estimated $246M increase.
- Primecap Management's biggest Q4 2016 reduction was Charles Schwab, cutting an estimated $265M.
- Primecap Management fully exited QIAGEN NV in Q4 2016, selling an estimated $534M.
- Primecap Management's ten largest holdings make up 33% of its $102B portfolio in Q4 2016.
- Primecap Management opened 14 new positions and closed 11 in Q4 2016.
- Primecap Management's portfolio value rose 1.4% quarter-over-quarter to $102B.
Based on Primecap Management's 13F filing for Q4 2016, filed 13 Feb 2017.